Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for quarter ended September 30, 2026.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging as of November 16, 2026
- Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.2
- Investors should review Exhibit 99.2 for updated pipeline, clinical, financing or corporate developments
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $51.6M, versus $29.4M, reflecting sharply higher clinical development spending
- Cash, equivalents and investments $463.4M, expected to fund operations through 2028 and key clinical readouts
- ZEPHYR-2 Phase 3 startup underway for schizophrenia, with topline results expected in 2028
- VISTA Phase 2 enrollment ongoing in approximately 300 ADP participants, with topline results expected second half 2027
- ML-007C-MA prioritized while significant investment in early-stage programs is paused, concentrating capital on lead assets
Item EX-99.2 · Exhibit EX-99.2
- Corporate presentation dated November 16, 2026 highlights ML-007C-MA as the lead schizophrenia and Alzheimer’s disease psychosis asset
- ZEPHYR-1 met its primary endpoint, with PANSS effect size 0.37 and cognitive composite effect size 0.51
- ML-007C-MA showed 7.1% discontinuations due to treatment-emergent adverse events and 2.0% due to gastrointestinal events
- Planned ZEPHYR-2 pivotal study could support an NDA, subject to FDA End-of-Phase 2 feedback
- Cash of approximately $463M supports a runway through 2028, funding near-term clinical milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.